Opportunity for comment:
Posted: 7th of July, 2017
GSA members are invited to comment on the second set of draft content in the Clinical practice guidelines for the prevention and diagnosis of lung cancer. Cancer Council Australia is currently in the process of developing these guidelines.
Feedback will be accepted during the public consultation period from 3 July 2017 to Saturday 30 July 2017. There are seven draft questions available for comment:
Diagnosis and staging:
- When is IHC required for subtyping of NSCLC and what is the optimal IHC panel?
- What specimen types are suitable for mutation testing in NSCLC patients?
- In people undergoing lung cancer evaluation, does concurrent diagnosis and staging provide greater benefit for patient outcomes compared to sequential testing for diagnosis followed by staging?
- For patients undergoing workup for known or suspected lung cancer, what is the optimal timing of PET/CT? Before or after tissue biopsy confirmation?
- Does routine follow-up improve patient outcomes in people who have curative intent treatments for lung cancer?
- What are the optimal follow-up tests for people with lung cancer who have had curative intent treatment?
- What is the optimal model (provider) of care for the follow up of people with lung cancer who have had curative intent treatment?
Please see also the complete list of clinical questions included in the guideline.
How to submit feedback
Detailed instructions on how to submit an online comment are available online. You may also comment by a reply email to this address.
All comments received by 30 July 2017 will be reviewed and considered by the Working Party, chaired by Prof Kwun Fong. If necessary we will contact individuals directly to obtain further clarification. Where appropriate, revisions will be made to the guidelines content following public consultation.